Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice.

[1]  T. Allen.  Long-circulating (sterically stabilized) liposomes for targeted drug delivery. , 1994, Trends in pharmacological sciences.

[2]  M. Bally,et al.  Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. , 1994, Cancer research.

[3]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[4]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[5]  D. Lasič,et al.  Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes , 1992, International journal of cancer.

[6]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[7]  K. Funato,et al.  Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. , 1992, Biochimica et biophysica acta.

[8]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[10]  M. Bally,et al.  Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. , 1990, Cancer letters.

[11]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[12]  M. Bally,et al.  The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. , 1990, Chemistry and physics of lipids.

[13]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[14]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[15]  M. Bally,et al.  Generating and loading of liposomal systems for drug-delivery applications , 1989 .

[16]  P. Cullis,et al.  Spontaneous vesiculation of large multilamellar vesicles composed of saturated phosphatidylcholine and phosphatidylglycerol mixtures. , 1988, Biochemistry.

[17]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Williams,et al.  Imaging in rheumatoid arthritis using liposomes labelled with technetium. , 1986, British medical journal.

[19]  S. Kojima,et al.  Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D. V. Von Hoff,et al.  Mitoxantrone: a new anticancer drug with significant clinical activity. , 1986, Annals of internal medicine.

[21]  M. Bally,et al.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.

[22]  L. Mayer,et al.  Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. , 1985, Biochimica et biophysica acta.

[23]  M. Bally,et al.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. , 1985, Biochimica et biophysica acta.

[24]  I. Smith,et al.  Mitoxantrone (novantrone): a review of experimental and early clinical studies. , 1983, Cancer treatment reviews.

[25]  Y. Barenholz,et al.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. , 1982, Cancer research.

[26]  F. Szoka,et al.  Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. , 1982, European journal of cancer & clinical oncology.

[27]  U. Pick,et al.  Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures. , 1981, Archives of biochemistry and biophysics.

[28]  B. Sikic,et al.  Liposomal protection of adriamycin-induced cardiotoxicity in mice. , 1980, Cancer research.

[29]  Leaf Huang,et al.  Enhanced delivery and antitumor effect of doxorubicin encapsulated in long-circulating liposomes , 1994 .

[30]  M. Bally,et al.  The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin , 1994 .

[31]  R. Schwendener,et al.  Preclinical and Clinical Experience with Liposome-Encapsulated Mitoxantrone , 1994 .

[32]  L. Williams,et al.  Technetium-labelled liposome imaging for deep-seated infection. , 1985, The British journal of radiology.